CDH1 and neoplasm: This study is the first to report the presence of the binding site AUGCAGU for miR-217 in the 3′ UTR region of E-cadherin, which precisely matches the UACGUCA sequence in miR-217, providing a theoretical basis for miR-217 as a potential target for tumor inhibition.